Sun, Oct 19, 2025
[Archive]
Volume 33, Issue 159 (July & August 2025)
J Adv Med Biomed Res 2025, 33(159): 309-318 |
Back to browse issues page
Ethics code: Rusafa, No. 126249, on December 18, 2024
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
A. Hassoun M, AA. Abass E. Assessment of Adipsin and Lipid Profile in Iraqi Women with Thyroid Dysfunction. J Adv Med Biomed Res 2025; 33 (159) :309-318
URL: http://journal.zums.ac.ir/article-1-7775-en.html
URL: http://journal.zums.ac.ir/article-1-7775-en.html
1- Department of Chemistry, College of Education for Pure Science Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq
2- Department of Chemistry, College of Education for Pure Science Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq ,eiman.aa.a@ihcoedu.uobaghdad.edu.iq
2- Department of Chemistry, College of Education for Pure Science Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq ,
Abstract: (186 Views)
Background & Objective: Thyroid dysfunction (TD) and diabetes mellitus (DM) are among the most common endocrine disorders, both strongly linked to metabolic dysregulation. Adipsin, an adipokine, has been implicated in obesity-related cardiometabolic diseases and may serve as a potential biomarker. This study aimed to evaluate serum adipsin and lipid profile levels in Iraqi women with thyroid dysfunction, to investigate their diagnostic value, and to assess whether these patients are at increased risk of cardiovascular disease.
Materials & Methods: This case–control study included 130 women aged 25–55 years, of whom 100 had thyroid dysfunction and 30 served as healthy controls. Patients were divided into four groups: G1, hypothyroidism (n=25); G2, hypothyroidism with DM (n=25); G3, hyperthyroidism (n=25); and G4, hyperthyroidism with DM (n=25). Serum adipsin and lipid parameters, including triglycerides (TG), total cholesterol (Chol), low-density lipoprotein cholesterol (LDL-ch), and high-density lipoprotein cholesterol (HDL-ch), were measured and compared across groups.
Results: There were an important elevation in Triglycerides (TG), total Cholesterol (Chol), and Low-Density Lipoprotein Cholesterol (LDL-ch) levels in G2 and G3, also TG was significant increase in G3 and G4, in addition a significant elevation in LDL-ch in G4.While there were An important decrease in High-Density Lipoprotein Cholesterol (HDL-ch) levels in all patient groups. Adipsin levels were significantly higher in all patient groups than in the control group, according to the research.
Conclusion: The current study suggests that Adipsin may have a potential role as a diagnostic and follow-up marker of DM in thyroid disease patients, but further studies are needed to confirm this. Compared to hyperthyroidism, patients with hypothyroidism may be at risk for cardiovascular diseases. Additionally, adipsin may be considered a diagnostic marker for thyroid dysfunction.
Type of Study: Original Research Article |
Subject:
Medical Biology
Received: 2025/07/1 | Accepted: 2025/09/9 | Published: 2025/09/29
Received: 2025/07/1 | Accepted: 2025/09/9 | Published: 2025/09/29
References
1. Kargar S, Tabatabaei SM, Okati-Aliabad H, Rad HI. Prevalence of Thyroid Dysfunction Disorders among Adult Populations in the Middle-East: A Systematic Review and Meta-analysis. Open Public Health J. 2024;17(1). [DOI:10.2174/0118749445317174240827052511]
2. Saleh DS, Othman MS. Exploring the challenges of diagnosing thyroid disease with imbalanced data and machine learning: A systematic literature review. Baghdad Sci J. 2024;21(3):1119-36. [DOI:10.21123/bsj.2023.8544]
3. Mefford L. Disorders of endocrine control of growth and metabolism. Noris TL, ed Porth's Pathophysiology: Concepts of Altered Health States: Wolters Kluwer; 2025. p. 1235-80.
4. Somerall D, Somerall W. Thyroid disorders in women: evaluation, diagnosis, and management. Clin J Nurse Pract Women's Health. 2025;2(2):79-87. [DOI:10.1891/CJNPWH-2512]
5. Abubakar MZ, Abdulsalam K, Yahaya IA. Thyroid hormones profile of patients with type 2 diabetes mellitus in Kano, Nigeria. Ann Afr Med. 2020;3(1). [DOI:10.4081/aamr.2020.112]
6. Iedan MA, Al-Rubaei ZMM. Chitotriosidase-1 levels in Iraqi Type 2 Diabetic Patients with Thyroid Disorders. Ibn AL-Haitham J Pure App Sci. 2019;32(2):45-50. [DOI:10.30526/32.2.2138]
7. Al-Odat I, Al-Fawaeir S, Al-Mahmoud MH. Study of the association between thyroid dysfunction and serum lipid abnormalities. Biomed Rep. 2024;21(4):138. [DOI:10.3892/br.2024.1826] [PMID] [PMCID]
8. Abdollahi A, Nozarian Z, Salarvand S, Pourebrahimi E. The Link Between High Sensitivity Troponin T Levels and Outcomes Among Patients with Congestive Heart Failure: A Systematic Review and Meta-Analysis Study. Iran J Pathol. 2025;20(3):245-56. [DOI:10.30699/ijp.2025.2057561.3440] [PMID] [PMCID]
9. Taşdemir E, Şermet A. The relationship between plasma adipsin, adiponectin, vaspin, visfatin, and leptin levels with glucose metabolism and diabetes parameters. diabetes. 2019;15:21. [DOI:10.14744/hnhj.2019.62534]
10. Bajilan SI. Evaluation of Adipose Tissue Hormones and Tumor Necrosis Factor in Patients with Endometriosis. J Contemp Med Sci. 2024;10(5):340-5. [DOI:10.22317/jcms.v10i5.1616]
11. Byeon HJ, Chae MK, Ko J, Lee EJ, Kikkawa DO, Jang SY, et al. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy. Invest Ophthalmol Vis Sci. 2023;64(11):13. [DOI:10.1167/iovs.64.11.13] [PMID] [PMCID]
12. Duzenli FN, Yurtcu E, Keyif B, Basbug A. Unmasking metabolic clues: adipsin, irisin and osteopontin as biomarkers in polycystic ovary syndrome and their impact on metabolic dynamics: a case-control study. Ginekol Pol. 2025;96(7):532-41. [DOI:10.5603/gpl.102676] [PMID]
13. Gómez-Banoy N, Guseh JS, Li G, Rubio-Navarro A, Chen T, Poirier B, et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med. 2019;25(11):1739-47. [DOI:10.1038/s41591-019-0610-4] [PMID] [PMCID]
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. [DOI:10.1093/clinchem/18.6.499] [PMID]
15. Brewster S, Bartholomew J, Holt RIG, Price H. Non-attendance at diabetes outpatient appointments: a systematic review. Diabet Med. 2020;37(9):1427-42. [DOI:10.1111/dme.14241] [PMID]
16. Dawood A, Abed B, Farhan L, Salman I. Evaluation of Neudesin Level in A sample of Iraqi Patients with Hypothyroidism. Iraqi J Sci. 2024:6205-13. [DOI:10.24996/ijs.2024.65.11.1]
17. Abass E, Al-Sa'adsi W, Moslem M. Retinol-binding protein-4 and progranulin in Iraqi women with thyroid disorder. Int J Drug Deliv Technol. 2021;11(1):36-41.
18. Mintziori G, Veneti S, Poppe K, Goulis DG, Armeni E, Erel CT, et al. EMAS position statement: Thyroid disease and menopause. Maturitas. 2024;185:107991. [DOI:10.1016/j.maturitas.2024.107991] [PMID]
19. 19 Ayatollahi A, Moosavi Z, Ayatollahi H. Serum C-reactive Protein Levels About Insulin Resistance and Beta Cell Function in Iranian Women with Subclinical Hypothyroidism. Iran J Pathol, 2024;19(3):326-31. [DOI:10.30699/ijp.2024.2015823.3213] [PMID] [PMCID]
20. Kalra S, Aggarwal S, Khandelwal D. Thyroid Dysfunction and Type 2 Diabetes Mellitus: Screening Strategies and Implications for Management. Diabetes Ther. 2019;10(6):2035-44. [DOI:10.1007/s13300-019-00700-4] [PMID] [PMCID]
21. Salman Jasim H, Khalid Shafeeq N, Abass EAA. Vitamin D Level and its Relation with the Newly Diagnosed Diabetic Neuropathy in Women with Hypothyroidism. Arch Razi Inst. 2022;77(3):1139-45.
22. Al-Rubaei ZM, Abdulhadi GH, Alrubaye IM, Alrugaibi AH. Comparative study of fetuin-a levels l Iraqi diabetic patients with hyper and thyroid disorder. Biochem Cell Arch. 2021;21(1):53-7.
23. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011;2011:439463. [DOI:10.4061/2011/439463] [PMID] [PMCID]
24. Milek M, Moulla Y, Kern M, Stroh C, Dietrich A, Schön MR, et al. Adipsin Serum Concentrations and Adipose Tissue Expression in People with Obesity and Type 2 Diabetes. Int J Mol Sci. 2022;23(4):2222. [DOI:10.3390/ijms23042222] [PMID] [PMCID]
25. Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158(1):41-53. [DOI:10.1016/j.cell.2014.06.005] [PMID] [PMCID]
26. Farhan LO, Abed BA, Dawood A. Comparison study between adipsin levels in sera of Iraqi patients with diabetes and neuropathy. Baghdad Sci J. 2023;20(3):726-33. [DOI:10.21123/bsj.2022.7408]
27. Dare A, Chen SY. Adipsin in the pathogenesis of cardiovascular diseases. Vascul Pharmacol. 2024;154:107270. [DOI:10.1016/j.vph.2023.107270] [PMID] [PMCID]
28. Raoof EM, Ahmed HS. Circulating adipsin as biomarker and its implication in type 2 diabetes mellitus. Int J Drug Deliv Technol. 2022;12(2):588-93.
29. Jawzal K, Hami M, Mohammed L, Ibrahiem A. The relationship between thyroid hormones and lipid profile in subclinical hypothyroidism female patients. Baghdad J Biochem Appl Biol Sci. 2022;3(03):200-9. [DOI:10.47419/bjbabs.v3i03.137]
30. Maleki N, Kazerouni F, Hedayati M, Rahimipour A, Maleki H. Assessment of cardiovascular risk factors in patients with subclinical hypothyroidism. Acta Cardiol. 2016;71(6):691-7. [DOI:10.1080/AC.71.6.3178188] [PMID]
31. Karthick N, Dillara K, Poornima KN, Subhasini AS. Dyslipidaemic changes in women with subclinical hypothyroidism. J Clin Diagn Res. 2013;7(10):2122. [DOI:10.7860/JCDR/2013/5777.3448] [PMID] [PMCID]
32. Neves C, Alves M, Medina JL, Delgado JL. Thyroid diseases, dyslipidemia and cardiovascular pathology. Rev Port Cardiol. 2008;27(10):1211-36.
33. Jouad HA. Atherogenic indications in thyroidism patients and risk of cardiovascular diseases. Iraqi J Mark Res Consum Prot. 2023;15(2):74-82. [DOI:10.28936/jmracpc15.2.2023.(8)]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Farname Inc. is licensed under CC BY-NC 4.0
